FHI Clinical launches as full-service clinical research organization

April 9, 2019

FHI Clinical, Inc. announces its launch today as a full-service contract research organization (CRO) with the global expertise, responsive approaches and proven solutions to manage complex clinical research in resource-limited settings around the world.

With a focus on mission-driven clinical research, FHI Clinical addresses unmet research needs across dozens of therapeutic areas, while supporting the development of life-saving vaccines and medicines. Whether working from a state-of-the-art facility or in a low-tech, rural setting, FHI Clinical provides services tailored to meet its clients’ diverse study needs, from protocol design and site assessment to trial planning, implementation and management.

FHI Clinical is led by Ted FitzGerald, who transitions from Director of Global Research Services (GRS), FHI 360 to President and CEO of the new company. In his more than a decade of work for FHI 360, FitzGerald led clinical research services, business development and administrative teams. The senior management team also includes:

  • George Belai, Vice President, Global Strategy
  • Claudia Christian, Vice President, Global Clinical Operations
  • Rebecca Johnson, Vice President, Business Operations

The FHI Clinical Board of Directors is composed of:

  • Edward Whitehorne (Chair), former Chair, Board of Directors, FHI 360
  • Patrick Fine (Vice Chair), CEO, FHI 360
  • Greg Connors, Consultant and former Senior Vice President, Corporate Development, Quintiles
  • Pamela Myers, Chief Human Resources Officer, FHI 360
  • Albert Siemens, retired Chair and CEO, FHI 360

FHI Clinical operates as an independent, commercial subsidiary of FHI 360, an international nonprofit working to improve the health and well-being of people in the United States and around the world. The company benefits from FHI 360’s nearly 50-year history of research and its past successes creating and growing CROs. FHI Clinical is located in downtown Durham, North Carolina.

“FHI 360’s global reach and reputation for excellence has enabled us to provide technical, regulatory and cultural expertise in regions where the needs for clinical research are greatest,” said Ted FitzGerald, FHI Clinical president and CEO. “As an independent subsidiary, FHI Clinical has the best of both worlds — access to FHI 360’s global platform and technical expertise, and the flexibility to implement systems and processes designed for both commercial and public sector clients.”

FHI Clinical joins FHI 360’s family of organizations, which includes two other recently launched subsidiaries: the social impact investing company FHI Ventures, and the nonprofit FHI Partners, which creates strategic partnerships with foundations and corporations.

“FHI Clinical will enable us to further expand our social impact,” said Patrick Fine, Chief Executive Officer of FHI 360. “Each member of the FHI 360 family operates differently, yet together we are guided by the same vision: to create a world in which all individuals and communities have the opportunity to reach their highest potential. I’m confident that FHI Clinical will deliver on that mission.”

news archive

Evaluation of baricitinib versus dexamethasone for adults hospitalized with COVID-19 in the global ACTT-4 study

September 7, 2022
The global ACTT-4 study, supported by FHI Clinical, evaluated baricitinib vs dexamethasone for adults hospitalized with COVID-19. This trial is the fourth and final stage in a series of phase 3, randomized, double-blind, placebo-controlled trials to evaluate the clinical efficacy and safety of investigational therapeutic agents in hospitalized adults with laboratory-confirmed COVID-19.

Read more »

FHI Clinical announces the closing of its acquisition of the clinical trials business of South Africa-based Triclinium Clinical Development (TCD)

February 8, 2022
FHI Clinical Inc. announces today the official closing of its acquisition of the clinical trials business of Triclinium Clinical Development Proprietary Limited (TCD), a full-service, South Africa-based CRO. With the acquisition, FHI Clinical expands its share of the infectious disease (ID) clinical development market and becomes the dominant service provider in sub-Saharan Africa.

Read more »

Share this post